- Conditions
- Hemophilia A
- Interventions
- Emicizumab, FEIBA, rFVIIa
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–40
of 40
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Congenital Bleeding Disorder, Healthy
- Interventions
- activated recombinant human factor VII
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 60 Years · Male only
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
- Interventions
- coagulation factor VIIa [recombinant]-jncw
- Drug
- Lead sponsor
- American Thrombosis and Hemostasis Network
- Network
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more
- Conditions
- Other Haemostasis Disorder, Haemorrhagic Cystitis
- Interventions
- activated recombinant human factor VII
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 3
- States / cities
- Chapel Hill, North Carolina • Houston, Texas
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Interventions
- activated recombinant human factor VII
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 2 Years and older · Male only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 13
- States / cities
- Berkeley, California • Los Angeles, California • Chicago, Illinois + 9 more
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Interventions
- activated recombinant human factor VII, Feiba VH
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Male only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Plainsboro, New Jersey
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Interventions
- eptacog alfa (activated)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Male only
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
- Interventions
- MarzAA
- Biological
- Lead sponsor
- Catalyst Biosciences
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Washington D.C., District of Columbia
- Conditions
- Acquired Bleeding Disorder, Bleeding During/Following Surgery
- Interventions
- standard therapy, placebo, activated recombinant human factor VII
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • Duarte, California • Baltimore, Maryland + 4 more
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Interventions
- eptacog alfa (activated), Feiba VH
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Up to 20 Years · Male only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Berkeley, California • Los Angeles, California + 16 more
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Interventions
- vatreptacog alfa (activated), eptacog alfa (activated)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Los Angeles, California • Orange, California + 10 more
- Conditions
- Hemophilia A
- Interventions
- Nuwiq, Octanate, Wilate, Emicizumab, Recombinant factor VIIa (rFVIIa), Activated prothrombin complex concentrate (aPCC)
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Congenital Bleeding Disorder, Congenital FVII Deficiency
- Interventions
- activated recombinant human factor VII, Fresh frozen plasma (Source unspecified), Plasma-derived FVII (LFB), Prothrombin Complex conc. (PCC), Plasma-derived FVII conc. (pdFVII Baxter), Plasma-derived FVII conc. (pdFVII PFL)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Not listed
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- Recombinant Factor VIIa BI (rFVIIa BI)
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 12 Years to 65 Years · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Acquired Bleeding Disorder, Trauma
- Interventions
- activated recombinant human factor VII
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Plainsboro, New Jersey
- Conditions
- Hemophilia
- Interventions
- Coagulation Factor VIIa (Recombinant)
- Biological
- Lead sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
- Industry
- Eligibility
- 12 Years to 65 Years · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Atlanta, Georgia • New Orleans, Louisiana + 2 more